These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18424161)

  • 21. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Alvino A; Magatti M; Silini AR; Cardinale A; Paldino E; Fusco FR; Parolini O
    J Cell Mol Med; 2019 Feb; 23(2):1581-1592. PubMed ID: 30585395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
    Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
    J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
    Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J
    J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
    Hansson O; Petersén A; Leist M; Nicotera P; Castilho RF; Brundin P
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8727-32. PubMed ID: 10411943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.
    Hansson O; Nylandsted J; Castilho RF; Leist M; Jäättelä M; Brundin P
    Brain Res; 2003 Apr; 970(1-2):47-57. PubMed ID: 12706247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.
    Tabrizi SJ; Workman J; Hart PE; Mangiarini L; Mahal A; Bates G; Cooper JM; Schapira AH
    Ann Neurol; 2000 Jan; 47(1):80-6. PubMed ID: 10632104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.
    Decressac M; Wright B; Tyers P; Gaillard A; Barker RA
    Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.
    Naver B; Stub C; Møller M; Fenger K; Hansen AK; Hasholt L; Sørensen SA
    Neuroscience; 2003; 122(4):1049-57. PubMed ID: 14643771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
    Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
    Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
    Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S
    J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
    Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
    Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.